With no “cure,” neovascular age-related macular degeneration (or wet AMD) remains a key disease state for numerous pharmaceutical companies.
Here is a brief overview of where some of the investigations stand, along with the most recent information on clinical trials (all information is from company information):
Aerpio Therapeutics is developing ARP-1536 is a humanized monoclonal antibody that targets the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP). Tie2 activity is downregulated by two mechanisms: deactivation of active Tie2 by VE-PTP and binding of the non-activating ligand angiopoietin-2 (Ang-2). According to the company, Based on the long half-life of monoclonal antibodies, ARP-1536 has the potential to be administered on a monthly to quarterly basis.